Previous 10 | Next 10 |
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings the consensus holdings were updated, 6 stocks were removed and 6 added from the un...
Cathie Wood has won investors’ confidence with her funds’ significant gains last year. The renowned investor believes that investing in innovation is the key to success. And Wall Street analysts are bullish on Zillow (Z) and Fate Therapeutics (FATE), which are held in Woodȁ...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the univ...
Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48...
Tesla (NASDAQ:TSLA) stirred fresh interest in the electric-vehicle sector on Friday following its well-publicized AI event the day before. However, the sector's Friday rally was really led by gains in Lordstown (NASDAQ:RIDE), which displayed its product at a separate showcase. The space as a ...
Gainers: Greenpro Capital (NASDAQ:GRNQ) +61%. GeoVax Labs (NASDAQ:GOVX) +49%. Flora Growth Corp. (NASDAQ:FLGC) +31%. Pixelworks (NASDAQ:PXLW) +20%. XTL Biopharmaceuticals (NASDAQ:XTLB) +18%. Leju Holdings (NYSE:LEJU) +17%. Zhihu (NYSE:ZH) +17%. Organovo (NASDAQ:ONVO) +16%. Creatd (NASDAQ:CRTD...
Shares of Fate Therapeutics (NASDAQ: FATE) , a clinical-stage biotechnology company, are sliding in response to interim data from ongoing clinical trials with two of its new drug candidates. Investors unimpressed with the company's new approach to cancer drug development shaved 17.9...
Gainers: GeoVax Labs (NASDAQ:GOVX) +52%, Flora Growth (NASDAQ:FLGC) +30%, XTL Biopharmaceuticals (NASDAQ:XTLB) +17%, Organovo (NASDAQ:ONVO) +16%, Impel NeuroPharma (NASDAQ:IMPL) +11%. Losers: Progenity (NASDAQ:PROG) -55%, Sonnet BioTherapeutics (NA...
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rituximab Following Autologous CD19 CAR T-cell Therapy 8 of 11 Patients in FT516...
Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holds 48 s...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...